search
Back to results

Changes in Cardiac Deformation Following Physiologic Alterations and Inotropic Support.

Primary Purpose

Heart Failure, Diastolic, Aortic Valve Stenosis, Monitoring, Physiologic

Status
Completed
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Levosimendan
Milrinone
Sponsored by
Sahlgrenska University Hospital, Sweden
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Heart Failure, Diastolic focused on measuring Transesophageal, Echocardiography, Milrinone, Levosimendan, Strain, Deformation, Diastole, Afterload, Preload, Systole

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subject has aortic valve stenosis
  • Subject is scheduled for open heart aortic valve replacement with or without simultaneous coronary artery bypass grafting

Exclusion Criteria:

  • Less than normal systolic function, defined as ejection fraction less than 0,5
  • Non-sinus rhythm
  • Any major surgical complication
  • Problems understanding the informed consent

Sites / Locations

  • Thoraxoperation/TIVA, Sahlgrenska universitetssjukhuset

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Levosimendan

Milrinone

Arm Description

st dose: 12 µg/kg iv bolus for 10 min followed by 0,1 µg/kg/min for 20 min. nd dose: 12 µg/kg iv bolus for 10 min followed by 0,2 µg/kg/min for 20 min.

st dose: 48 µg/kg iv bolus for 10 min followed by 0,4 µg/kg/min for 20 min. nd dose: 48 µg/kg iv bolus for 10 min followed by 0,8 µg/kg/min for 20 min.

Outcomes

Primary Outcome Measures

Change in diastolic strain rate
Diastolic strain rate defined as peak E wave strain rate as measured by 2D speckle tracking of the left ventricular wall.

Secondary Outcome Measures

Change in systolic strain and strain rate
Systolic strain and strain rate defined as their respective peak values during systole, measured by 2D speckle tracking of the left ventricular wall.
Change in cardiac output
Measured through pulmonary artery thermodilution as liters per minute. A baseline measurement is done before infusion is started.

Full Information

First Posted
March 31, 2015
Last Updated
May 8, 2017
Sponsor
Sahlgrenska University Hospital, Sweden
search

1. Study Identification

Unique Protocol Identification Number
NCT02408003
Brief Title
Changes in Cardiac Deformation Following Physiologic Alterations and Inotropic Support.
Official Title
What Are the Changes in Cardiac Deformation Variables and Hemodynamic Parameters Following Changes in Cardiac Loading Conditions and After Administration of Two Different Inotropic Drugs.
Study Type
Interventional

2. Study Status

Record Verification Date
May 2017
Overall Recruitment Status
Completed
Study Start Date
March 2014 (Actual)
Primary Completion Date
May 2016 (Actual)
Study Completion Date
May 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Sahlgrenska University Hospital, Sweden

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The investigators want to compare the effects of two drugs, levosimendan and milrinone, on cardiac muscle, both in terms of contractility and relaxation. Half of the participants will be randomized to each drug. The effects will be measured through echocardiographic deformation analyses. Since deformation analyses could be dependent on different loading conditions of the heart, a second purpose of the study is to investigate the changes on deformation parameters after applied changes in preload and afterload, but also heart rate.
Detailed Description
Aortic stenosis is associated with myocardial hypertrophy and diastolic dysfunction. In patients undergoing open aortic valve replacement surgery due to stenosis, the investigators want to compare the effect on myocardial relaxation between two commonly used drugs, levosimendan and milrinone, using catheter-based measurements in combination with echocardiographic evaluation. Standard anaesthesia and surgical care for these patients is performed. After surgery is completed and the participant is transferred to the intensive care unit, the studies are performed during general anaesthesia and the participants still connected to a respirator with controlled ventilation. Echocardiographic data will be collected simultaneously with hemodynamic parameters - first at two control measurements, then after each of two different doses of the drug. Preload, afterload and heart rate will be kept stable during this intervention. The echocardiographic data is later analyzed offline for strain and strain rate. To further investigate the dependency of strain and strain rate on changes in preload, afterload, and heart rate, these variables are consecutively changed prior to drug administration. For this purpose, all patients first have their baseline data recorded, thereafter are paced at two different rates, then preload and afterload is altered by passive leg elevation and phenylephrine, respectively. Hemodynamic and echocardiographic data are collected simultaneously at baseline and after each intervention. Before administration of the drugs, baseline conditions are restored.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure, Diastolic, Aortic Valve Stenosis, Monitoring, Physiologic, Physiology
Keywords
Transesophageal, Echocardiography, Milrinone, Levosimendan, Strain, Deformation, Diastole, Afterload, Preload, Systole

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Levosimendan
Arm Type
Experimental
Arm Description
st dose: 12 µg/kg iv bolus for 10 min followed by 0,1 µg/kg/min for 20 min. nd dose: 12 µg/kg iv bolus for 10 min followed by 0,2 µg/kg/min for 20 min.
Arm Title
Milrinone
Arm Type
Experimental
Arm Description
st dose: 48 µg/kg iv bolus for 10 min followed by 0,4 µg/kg/min for 20 min. nd dose: 48 µg/kg iv bolus for 10 min followed by 0,8 µg/kg/min for 20 min.
Intervention Type
Drug
Intervention Name(s)
Levosimendan
Other Intervention Name(s)
Daxim, Simdax
Intervention Description
Data is collected at baseline as two controls. Three physiological interventions follows, and data is collected after each: Increasing heart rate in two steps by atrial pacing through a temporary pacemaker. Raising cardiac preload by increasing central venous pressure through leg elevation. Raising cardiac afterload by increasing systemic vascular resistance through administering of phenylephrine. Baseline is restored, and data is collected before drug adminstration as two controls, then after a first (half) dose, and finally after a second (full) dose.
Intervention Type
Drug
Intervention Name(s)
Milrinone
Other Intervention Name(s)
Primacor, Corotrop, Milicor
Intervention Description
Data is collected at baseline as two controls. Three physiological interventions follows, and data is collected after each: Increasing heart rate in two steps by atrial pacing through a temporary pacemaker. Raising cardiac preload by increasing central venous pressure through leg elevation. Raising cardiac afterload by increasing systemic vascular resistance through administering of phenylephrine. Baseline is restored, and data is collected before drug adminstration as two controls, then after a first (half) dose, and finally after a second (full) dose.
Primary Outcome Measure Information:
Title
Change in diastolic strain rate
Description
Diastolic strain rate defined as peak E wave strain rate as measured by 2D speckle tracking of the left ventricular wall.
Time Frame
After each physiologic intervention, and at 30 and 60 min after start of iv infusion of drug.
Secondary Outcome Measure Information:
Title
Change in systolic strain and strain rate
Description
Systolic strain and strain rate defined as their respective peak values during systole, measured by 2D speckle tracking of the left ventricular wall.
Time Frame
After each physiologic intervention, and at 30 and 60 min after start of iv infusion of drug.
Title
Change in cardiac output
Description
Measured through pulmonary artery thermodilution as liters per minute. A baseline measurement is done before infusion is started.
Time Frame
After each physiologic intervention, and at 30 and 60 min after start of iv infusion of drug.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject has aortic valve stenosis Subject is scheduled for open heart aortic valve replacement with or without simultaneous coronary artery bypass grafting Exclusion Criteria: Less than normal systolic function, defined as ejection fraction less than 0,5 Non-sinus rhythm Any major surgical complication Problems understanding the informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sven-Erik Ricksten, Professor
Organizational Affiliation
Dept of Anesthesia and Intensive Care, University of Gothenburg
Official's Role
Principal Investigator
Facility Information:
Facility Name
Thoraxoperation/TIVA, Sahlgrenska universitetssjukhuset
City
Göteborg
ZIP/Postal Code
413 45
Country
Sweden

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Changes in Cardiac Deformation Following Physiologic Alterations and Inotropic Support.

We'll reach out to this number within 24 hrs